Circadian Technologies, a biologic drug developer, has launched the first phase I clinical trial of VGX-100, its fully human monoclonal antibody against the human VEGF-C protein.
The study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumors. VGX-100 will be administered both as monotherapy, as well as in combination with other anti-angiogenic agents.
"We are extremely proud to have completed the translation of VGX-100 from early discovery to the clinical development stage,” said Robert Klupacs, CEO of Circadian. “We are committed to improving outcomes for patients suffering from cancer, and believe that VGX-100, especially when combined with existing therapies, could make a significant difference.”
Results are expected to be available in the second half of 2012.